Harvard Bioscience EBIT

Harvard Bioscience posts a EBIT of $50M as of March 2026. That compares with $-43M in the prior-year period — up 216.4% year over year. That is below the Healthcare sector average of $23B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Harvard Bioscience's EBIT was $-43M. The latest reading is $50M — a 216.4% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $23B is typical. Harvard Bioscience's $50M is lower that level. That is roughly 99.8% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Harvard Bioscience's financial statement story. At $50M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for HBIO's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $23B), and (3) consistency with growth and profitability. This page covers the first two; Harvard Bioscience's other metric pages and overview cover the third.